管理合并内科疾病的度洛西汀患者的临床要点。
Clinical pearls for the management of duloxetine patients with medical comorbidities.
作者信息
O'Connell Megan, VandenBerg Amy
机构信息
(Corresponding author) Clinical Pharmacy Specialist, Psychiatry and Neurology, University of Michigan Health, Ann Arbor, Michigan,
Clinical Pharmacy Specialist, Psychiatry and Neurology, University of Michigan Health, Ann Arbor, Michigan; Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan.
出版信息
Ment Health Clin. 2024 Dec 2;14(6):313-320. doi: 10.9740/mhc.2024.12.313. eCollection 2024 Dec.
Abstract
The effective use of duloxetine can be complicated by acute kidney injury, acute and/or chronic hepatic dysfunction, dysphagia, enteral nutrition, and common pharmacokinetic interactions. This article aimed to review the pharmacological properties of duloxetine pertinent to its use and to discuss the management of duloxetine in patients with common acute and chronic medical comorbidities. Management strategies based on clinical data and expert opinion are reviewed in 3 patient cases.
摘要
度洛西汀的有效使用可能会因急性肾损伤、急慢性肝功能不全、吞咽困难、肠内营养以及常见的药代动力学相互作用而变得复杂。本文旨在综述度洛西汀与用药相关的药理学特性，并探讨合并常见急慢性内科疾病患者中度洛西汀的管理。通过3例患者病例回顾了基于临床数据和专家意见的管理策略。
相似文献
1
Clinical pearls for the management of duloxetine patients with medical comorbidities.管理合并内科疾病的度洛西汀患者的临床要点。
Ment Health Clin. 2024 Dec 2;14(6):313-320. doi: 10.9740/mhc.2024.12.313. eCollection 2024 Dec.
2
Duloxetine: clinical pharmacokinetics and drug interactions.度洛西汀：临床药代动力学和药物相互作用。
Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000.
3
Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.不同程度的肾功能损害对度洛西汀药代动力学的影响：一项单次剂量 I 期研究和 II/III 期试验稳态数据汇总分析。
Clin Pharmacokinet. 2010 May;49(5):311-21. doi: 10.2165/11319330-000000000-00000.
4
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.新型抗抑郁药的药理学和临床特征：对老年患者治疗的启示。
Drugs Aging. 2010 Aug 1;27(8):625-40. doi: 10.2165/11537140-000000000-00000.
5
Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.口服度洛西汀在患有重度抑郁症的儿童和青少年中的药代动力学。
Clin Pharmacokinet. 2014 Aug;53(8):731-40. doi: 10.1007/s40262-014-0149-y.
6
Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.度洛西汀口服给药在患者中的群体药代动力学：对给药推荐的意义
Clin Pharmacokinet. 2009;48(3):189-97. doi: 10.2165/00003088-200948030-00005.
7
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.AGA 临床实践更新：炎症性肠病患者的饮食和营养治疗：专家综述。
Gastroenterology. 2024 Mar;166(3):521-532. doi: 10.1053/j.gastro.2023.11.303. Epub 2024 Jan 23.
8
Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.度洛西汀的肝脏效应-III：使用外部数据源分析肝脏事件
Curr Drug Saf. 2008 May;3(2):154-62. doi: 10.2174/157488608784529215.
9
An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.度洛西汀在患有重度抑郁症的儿科患者中的开放标签安全性和药代动力学研究。
J Child Adolesc Psychopharmacol. 2012 Feb;22(1):48-55. doi: 10.1089/cap.2011.0072. Epub 2012 Jan 17.
10
Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital.一名日本住院患者过量服用度洛西汀与喹硫平及其他抗精神病药物后的药代动力学情况。
J Pharm Health Care Sci. 2021 Feb 3;7(1):6. doi: 10.1186/s40780-021-00189-9.
本文引用的文献
1
Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain.CYP2D6 抑制剂与 CYP2D6 类阿片类药物合用：与急诊疼痛就诊的相关性。
Clin Pharmacol Ther. 2024 Oct;116(4):1005-1012. doi: 10.1002/cpt.3314. Epub 2024 May 26.
2
Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction.联合使用抗抑郁药和β受体阻滞剂：临床显著 CYP2D6 药物相互作用的证据。
Pharmacotherapy. 2020 Jun;40(6):507-516. doi: 10.1002/phar.2406. Epub 2020 May 22.
3
A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications.细胞色素 P450 2D6 同工酶抑制剂分类证据的范围综述。
Clin Pharmacol Ther. 2020 Jul;108(1):116-125. doi: 10.1002/cpt.1768. Epub 2020 Feb 13.
4
Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.曲马多治疗强细胞色素 P450 2D6 抑制剂治疗患者的疼痛管理效果。
Pharmacotherapy. 2019 Jun;39(6):724-729. doi: 10.1002/phar.2269. Epub 2019 May 20.
5
Acute Urinary Retention and Acute Kidney Injury After Duloxetine Treatment: A Rare Case Report.度洛西汀治疗后急性尿潴留和急性肾损伤：一例罕见病例报告
J Clin Psychopharmacol. 2019 May/Jun;39(3):279-281. doi: 10.1097/JCP.0000000000001020.
6
Synergistic effect of polyethylene glycol and superdisintegrant on dissolution rate enhancement of simvastatin in pellet formulation.聚乙二醇和超级崩解剂对辛伐他汀丸剂配方溶出速率的协同增强作用。
Pharm Dev Technol. 2019 Jul;24(6):720-728. doi: 10.1080/10837450.2019.1584632. Epub 2019 Mar 26.
7
Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism.吸烟和非吸烟患者度洛西汀给药策略的差异：治疗药物监测揭示了对药物代谢的影响。
J Clin Psychiatry. 2018 Sep 4;79(5):17m12086. doi: 10.4088/JCP.17m12086.
8
Duloxetine Uses in Patients With Kidney Disease: Different Recommendations From the United States Versus Europe and Canada.度洛西汀在肾病患者中的应用：美国与欧洲及加拿大的不同推荐意见。
Am J Ther. 2019 Jul/Aug;26(4):e516-e519. doi: 10.1097/MJT.0000000000000737.
9
A review of Neuropathic Pain: From Guidelines to Clinical Practice.《神经性疼痛综述：从指南到临床实践》
Pain Ther. 2017 Dec;6(Suppl 1):35-42. doi: 10.1007/s40122-017-0087-0. Epub 2017 Nov 24.
10
Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.中风后抑郁症：美国心脏协会/美国中风协会为医疗保健专业人员发布的科学声明。
Stroke. 2017 Feb;48(2):e30-e43. doi: 10.1161/STR.0000000000000113. Epub 2016 Dec 8.
Zotero 插件